The OlympiAD trial was an open-label, randomized, phase III trial that determined that olaparib was superior, in terms of PFS, to the physician’s choice single-agent chemotherapy in patients with gBRCAm, HER2[−] advanced breast cancer [14,26]. Here, ERBB2 is linked to breast cancer.